אאוקרברן
trupharm marketing 1985 ltd. - medicinal charcoal; rhubarb; sennae folium; sulfur purified - טבליה - sennae folium 105 mg; rhubarb 25 mg; sulfur purified 50 mg; medicinal charcoal 180 mg - medicinal charcoal, combinations - medicinal charcoal, combinations - mild laxative, anti-flatulant.
equipment, devices, materials + accessories used in dental medicine
3m ישראל בע"מ - רופא שיניים - equipment, devices, materials + accessories used in dental medicine
millennium mpr/mps (pheonix plus and pheonix base nuclear medicine single detector systems)
ג'י אי מדיקל סיסטמס ישראל - צוות טכני - the system is general purpose product allowing for static, dynamic, whole body ,multigated cardiac tomographic and multigated tomographic nuclear medicine studies.
פאנדי 25 יח'מל (פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פאנדי 50 יח'מל ( פקטור 8 )
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פאנדי 100 יח'מל ( פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פאנדי 100 יח'מל 1500 יח' (פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
פלבוגאמה % 5 דיפ
medici medical ltd, israel - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 0.5 g / 10 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as:- congenital agammaglobulinaemia and hypogammaglobulinaemia- common variable immunodeficiency- severe combined immunodeficiency- wiskott aldrich syndromemyeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.children with congenital aids and recurrent infections.immunomodulation :idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.guillain barr? syndrome.kawasaki disease.allogeneic bone marrow transplantation
אקטסל
medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 5 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis and invasive haemophilus influenzae type b infection.
פוליאסל
medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 20 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis, poliomyelitis and invasive haemophilus influenzae type b infections.